Biotech stocks and exchange traded funds have endured a lengthy rough patch. And the pain has been particularly acute for small- and mid-cap fare. Over the past three years, the S&P Biotechnology Select Industry Index, which is chock full of smaller biotech stock, shed nearly 45%. That’s a staggering loss. Especially considering that over the [...] The post There Could Be Signs of Life for Biotech ETFs appeared first on ETF Trends .